Explore Annogen’s News
Annogen signs deal in which SuRE™ libraries are used for In-Vivo Capsid screening
Updates - December 2023 Annogen has signed a deal with an undisclosed gene therapy company for an AAV capsid screening project. For this project, Annogen will deliver its SuRE™ barcoding platform and downstream bioinformatics analysis to track tissue-specific biases...
Annogen introduces HEK293-INDX1™ – a clonal HEK293 cell line for inducible expression of toxic proteins such as Rep during AAV production
Updates - October 2023 Annogen is excited to share our latest break through in cellular engineering. We've successfully combined our SuRE™ promoter screening platform and our AIM™ integration site screening platform to establish HEK293 clones with near-zero baseline...
Annogen enters Contract Manufacturing market:AIM™ services and SuRE™ promoters
News – March 2023 AIM™ service (Annogen Integration Mapping: integration sites and their expression levels) was introduced in 2022 supporting cell engineering for cell therapy development. Now it is also available to the contract manufacturing market: manufacturing...
Annogen starts a collaboration with another leading agricultural multinational to research non-coding regulatory DNA using SuRE™ screening technology.
PRESS RELEASE The Netherlands, 26 January 2023 Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, started a collaboration with another top agricultural science and technology...
VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters
PRESS RELEASE Amsterdam, The Netherlands, 19 January 2023 Annogen to develop multiple CNS-cell specific promoters for VectorY programs VectorY Therapeutics, a biotech company developing innovative vectorized antibody approaches for the treatment of neurodegenerative...
Annogen Announces Research Project with Pfizer to TestNon-coding Genetic Sequences
PRESS RELEASE Amsterdam, 13 December 2022 Annogen will functionally annotate tens of thousands of disease-related non-coding sequence variants with the goal of aiding drug discovery Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the...
Annogen introduces AIM™ service
Identify favorable gene insertions and their expression levels (> 100,000 integrations in parallel) Annogen introduces a new service to identify gene insertions and asses their expression levels for >100,000 integrations in parallel. Using an adaptation of its...
Novel approach could aid selective breeding in cattle
Researchers aim to pinpoint non-gene components in DNA linked to production and welfare traits in cattle, gaining insights across species. Researchers are developing a method of identifying specific letters in the DNA code that govern the development of key physical...
SuRE technology finds hidden gene regulation
Many diseases are determined by differences in yet undiscovered gene regulation. Thanks to plasmids and 'barcodes', the SuRE assay can map this relatively easily and extensively for the entire human genome. 'The breakthrough came from the idea of using barcodes,' says...